Tempest Therapeutics Inc expected to post a loss of $2.60 a share - Earnings Preview
08/08/2025 21:09
Tempest Therapeutics Inc TPST.OQ TPST.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of $2.60 per share. The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Tempest Therapeutics Inc is $9.00, about 21.9% above its last closing price of $7.03 This summary was machine generated August 8 at 20:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T